Winzell Maria Sörhede, Ahrén Bo
Division of Medicine, Department of Clinical Sciences, Lund University, BMC, B11, SE-221 84 Lund, Sweden.
J Mol Endocrinol. 2008 Feb;40(2):93-100. doi: 10.1677/JME-07-0121.
Glucagon-like peptide 1 (GLP-1) augments glucose-stimulated insulin secretion (GSIS) through cAMP-induced activation of protein kinase A (PKA), and stimulates beta-cell proliferation and reduces beta-cell apoptosis in rodent islets. This study explored islet GSIS, PKA expression, and markers of apoptosis (caspase 3/7 activity) and proliferation (PKBalpha and pancreatic and duodenal homeobox gene 1, Pdx-1) after 2 weeks of treatment with the GLP-1 receptor agonist exendin-4 (2 nmol/kg once daily) in female mice with high-fat diet-induced insulin resistance (HFD; 58% fat by energy). Islets were isolated 20 h after the last exendin-4 injection, when effects of circulating exendin-4 had vanished. The glucose responsiveness in islets from HFD-fed mice at 8.3 mM glucose was reduced compared with islets from control mice fed a normal diet due to increased basal insulin secretion. However, GSIS increased in islets from HFD-fed exendin-4-treated animals (0.124+/-0.012 ng/h per islet in HFD-Ex-4 versus 0.062+/-0.010 in HFD, P=0.006). Furthermore, the insulin response to forskolin was increased (2.7+/-0.3 in HFD-Ex-4 versus 2.0+/-0.2 ng/h per islet in HFD, P=0.011) and PKAcat expression was increased, while PKAreg was reduced in islets from exendin-4-treated mice. In contrast, protein expression of PKBalpha, Pdx-1, and caspase 3/7 activity was not affected by exendin-4 treatment. We conclude that GLP-1 receptor activation in HFD-fed mice has durable effects on GSIS, in association with augmented signaling through the PKA pathway. These effects are seen beyond those induced by circulating exendin-4 already after 2 weeks of once-daily treatment in mice, whereas markers for islet proliferation and apoptosis were unaffected by this treatment.
胰高血糖素样肽1(GLP-1)通过cAMP诱导的蛋白激酶A(PKA)激活来增强葡萄糖刺激的胰岛素分泌(GSIS),并刺激啮齿动物胰岛中的β细胞增殖,减少β细胞凋亡。本研究探讨了在用胰高血糖素样肽-1受体激动剂艾塞那肽-4(2 nmol/kg,每日一次)治疗2周后,高脂饮食诱导胰岛素抵抗(HFD;能量的58%为脂肪)的雌性小鼠的胰岛GSIS、PKA表达以及凋亡(半胱天冬酶3/7活性)和增殖(蛋白激酶Bα和胰腺十二指肠同源盒基因1,Pdx-1)标志物的变化。在最后一次注射艾塞那肽-4后20小时分离胰岛,此时循环中的艾塞那肽-4的作用已经消失。由于基础胰岛素分泌增加,与喂食正常饮食的对照小鼠的胰岛相比,喂食HFD的小鼠的胰岛在葡萄糖浓度为8.3 mM时的葡萄糖反应性降低。然而,喂食HFD并接受艾塞那肽-4治疗的动物的胰岛中GSIS增加(HFD-Ex-4组为0.124±0.012 ng/小时·每个胰岛,HFD组为0.062±0.010,P = 0.006)。此外(此处英文原文有误,应为Furthermore),对福斯高林的胰岛素反应增加(HFD-Ex-4组为2.7±0.3,HFD组为2.0±0.2 ng/小时·每个胰岛,P = 0.011),并且PKAcat表达增加,而在接受艾塞那肽-4治疗的小鼠的胰岛中PKAreg降低。相比之下,艾塞那肽-4治疗对蛋白激酶Bα、Pdx-1的蛋白表达以及半胱天冬酶3/7活性没有影响。我们得出结论,在喂食HFD的小鼠中激活GLP-1受体对GSIS具有持久影响,与通过PKA途径增强的信号传导相关。在小鼠中每日一次治疗2周后,这些作用超出了循环中的艾塞那肽-4所诱导的作用,而胰岛增殖和凋亡标志物不受该治疗影响。